Mitra Hosseini | Drug Delivery | Best Researcher Award

Ms. Mitra Hosseini | Drug Delivery | Best Researcher Award

PhD Candidate at University of South Australia, Australia

Mahboubeh (Mitra) Hosseini-Kharat is a Ph.D. student at the University of South Australia specializing in vaccine development and gene expression research. Her research focuses on designing lipid-based nanocarriers for efficient gene delivery and nucleic acid-based cancer vaccines, employing advanced techniques such as microfluidic mixing, fluorescence microscopy, and flow cytometry. Hosseini-Kharat possesses strong analytical, problem-solving, and organizational skills, excelling in scientific writing, grant applications, and project management. She has received several prestigious awards, including the Global Talent Visa (Australia) and research grants from the Iran National Science Foundation. She has contributed significantly to various research projects in nanomedicine, cancer therapy, and vaccine formulations, with a focus on improving drug delivery systems. Her notable publications include several high-impact papers in respected journals such as Pharmaceutics and Molecular Therapy: Methods & Clinical Development. With extensive teaching and mentoring experience, she is a highly promising researcher in her field.

Professional Profile 

Education🎓

Mahboubeh (Mitra) Hosseini-Kharat has an extensive academic background in the fields of pharmacy and pharmaceutical sciences. She completed her Bachelor’s degree in Pharmaceutical Sciences from the University of Medical Sciences in Iran. Following that, she pursued a Master’s degree in Pharmaceutics at the same institution, where she gained a strong foundation in drug formulation, delivery systems, and nanomedicine. Hosseini-Kharat’s passion for advanced research led her to continue her academic journey as a Ph.D. candidate at the University of South Australia, where she is currently working on vaccine development and gene expression research. Her doctoral research focuses on designing lipid-based nanocarriers for gene delivery and nucleic acid-based cancer vaccines. This progression from a Bachelor’s to a Ph.D. has equipped her with a deep understanding of pharmaceutical sciences and advanced techniques in drug delivery and cancer therapy, furthering her expertise in nanomedicine and vaccine development.

Professional Experience📝

Mahboubeh (Mitra) Hosseini-Kharat has built a solid professional career in the field of pharmaceutical sciences, particularly in drug delivery and nanomedicine. After completing her Master’s degree in Pharmaceutics, she contributed to several research projects involving drug formulation and delivery systems. Her expertise further expanded during her role as a research assistant, where she investigated the potential of lipid-based nanocarriers for targeted drug delivery. Currently, Hosseini-Kharat is pursuing her Ph.D. at the University of South Australia, focusing on the development of gene-based vaccines and gene expression regulation. Her research aims to enhance vaccine efficacy and design innovative drug delivery systems to address complex diseases, including cancer. Along with her academic research, she has also participated in various scientific collaborations, contributing to the growing field of nanomedicine. Her professional experience highlights her dedication to advancing pharmaceutical sciences and her commitment to impactful research in healthcare innovation.

Research Interest🔎

Mahboubeh (Mitra) Hosseini-Kharat’s research interests focus on advancing pharmaceutical sciences, particularly in the areas of drug delivery, nanomedicine, and gene therapy. Her work explores the design and development of novel drug delivery systems, with a particular emphasis on lipid-based nanocarriers and their application in targeted drug delivery. She is dedicated to improving the efficacy of therapeutic agents, especially in the treatment of complex diseases like cancer. Currently, her Ph.D. research at the University of South Australia focuses on the development of gene-based vaccines and the regulation of gene expression to enhance immune responses and vaccine efficacy. Additionally, Hosseini-Kharat is deeply interested in the intersection of nanotechnology and medicine, aiming to create innovative solutions that can overcome the limitations of traditional drug delivery systems. Her research seeks to contribute to more effective and personalized treatments, fostering advancements in healthcare and therapeutic modalities.

Award and Honor🏆

Mahboubeh (Mitra) Hosseini-Kharat has received several prestigious awards and honors throughout her academic career, recognizing her outstanding contributions to pharmaceutical sciences and research. She was honored with a scholarship from the University of South Australia for her exceptional academic achievements and research potential. Additionally, her work on novel drug delivery systems has earned her multiple accolades, including recognition at various international conferences, where she presented groundbreaking findings on lipid-based nanocarriers and gene therapy. Hosseini-Kharat’s research has been praised for its potential to revolutionize cancer treatment and improve drug efficacy. She has also been awarded research grants and fellowships to support her work in the field of nanomedicine and gene-based vaccines. Her recognition highlights her commitment to advancing healthcare, with a particular focus on creating more effective and personalized treatment options through the integration of nanotechnology and pharmaceutical sciences.

Research Skill🔬

Mahboubeh (Mitra) Hosseini-Kharat possesses a diverse and advanced set of research skills in the field of pharmaceutical sciences, particularly in drug delivery systems and nanomedicine. She has a strong command over various laboratory techniques, including nanoparticle formulation, lipid-based nanocarriers, and gene delivery systems. Her proficiency in using state-of-the-art analytical tools, such as high-performance liquid chromatography (HPLC) and scanning electron microscopy (SEM), allows her to evaluate the stability, size, and release profiles of drug formulations. Additionally, Hosseini-Kharat is skilled in the preparation and testing of in vitro and in vivo models for evaluating drug efficacy and safety. Her expertise extends to the design and synthesis of innovative pharmaceutical formulations, as well as the development of gene-based vaccines. She is also adept at utilizing bioinformatics tools for data analysis, ensuring that her research findings are both accurate and meaningful. Her multidisciplinary approach reflects a high level of technical expertise and creativity in pharmaceutical research.

Conclusion💡

Mitra Hosseini-Kharat demonstrates exceptional strength as a researcher in the field of pharmaceutical sciences, particularly in vaccine development and gene expression. Her combination of innovative research, strong publication record, grant funding, and collaborative skills positions her as a strong candidate for the Best Researcher Award. While there are areas for growth, particularly in broadening her research exposure and increasing public engagement, her academic achievements and potential for future contributions make her a highly suitable candidate for this prestigious award.

Publications Top Noted✍️

  • Title: Microfluidic Optimization of PEI-Lipid Hybrid Nanoparticles for Efficient DNA Delivery and Transgene Expression
    Authors: M Hosseini Kharat, Anthony Wignall, Zelalem Addis Mekonnen, Benjamin Ung, Bradley Chereda, Kristen Bremmell, Branka Grubor-Bauk, Clive Prestidge
    Year: 2025
    Citation: DOI: 10.3390/pharmaceutics17040454

  • Title: Improvement of Power Conversion Efficiency of Quantum Dot-Sensitized Solar Cells by Doping of Manganese into a ZnS Passivation Layer and Cosensitization of Zinc-Porphyrin on a Modified Graphene Oxide/Nitrogen-Doped TiO<sub>2</sub> Photoanode
    Authors: M. Alavi, R. Rahimi, Z. Maleki, M. Hosseini-Kharat
    Year: 2020
    Citation: DOI: 10.1021/acsomega.0c00855

  • Title: Antiproliferative activity of morpholine-based compounds on MCF-7 breast cancer, colon carcinoma C26, and normal fibroblast NIH-3T3 cell lines and study of their binding affinity to calf thymus-DNA and bovine serum albumin
    Authors: M. Hosseini-Kharat, R. Rahimi, D. Zargarian, Z. Mehri Lighvan, A.A. Momtazi-Borojeni, T. Sharifi, E. Abdollahi, H. Tavakol, T. Mohammadi
    Year: 2019
    Citation: DOI: 10.1080/07391102.2018.1527724

  • Title: In vitro and in vivo antiproliferative activity of organo-nickel SCS-pincer complexes on estrogen responsive MCF7 and MC4L2 breast cancer cells. Effects of amine fragment substitutions on BSA binding and cytotoxicity
    Authors: M. Hosseini-Kharat, D. Zargarian, A.M. Alizadeh, K. Karami, M. Saeidifar, S. Khalighfard, L. Dubrulle, M. Zakariazadeh, J.-P. Cloutier, Z. Sohrabijam
    Year: 2018
    Citation: DOI: 10.1039/C8DT03079K

  • Title: A novel Pd(II) CNO pincer complex of MR (methyl red): synthesis, crystal structure, interaction with human serum albumin (HSA) in vitro and molecular docking
    Authors: M. Hosseini-Kharat
    Year: 2017
    Citation: DOI: 10.1039/C7NJ02156D

  • Title: NC Palladacycles and C,C-chelating phosphorus ylide complexes: Synthesis, X-ray characterization, and comparison of the catalytic activity in the Suzuki-Miyaura reaction
    Authors: K. Karami, M. Hosseini-Kharat, Z. Shirani-Sarmazeh, R. Zahedi-Nasab, C. Rizzoli, J. Lipkowski
    Year: 2016
    Citation: DOI: 10.1080/00958972.2016.1151876

  • Title: Synthesis, spectral characterization, crystal structure and in vitro DNA/protein binding studies of phosphorous ylide palladacyclic complexes containing azide group
    Authors: K. Karami, Z. Shirani-Sarmazeh, M. Hosseini-Kharat, J. Lipkowski, M. Saeidifar
    Year: 2015
    Citation: DOI: 10.1016/j.jphotobiol.2015.01.012

  • Title: In vitro cytotoxicity studies of palladacyclic complexes containing the symmetric diphosphine bridging ligand. Studies of their interactions with DNA and BSA
    Authors: K. Karami, M. Hosseini-Kharat, H. Sadeghi-Aliabadi, J. Lipkowski, M. Mirian
    Year: 2014
    Citation: DOI: 10.1016/j.ejmech.2013.11.042

  • Title: Polyethylene glycol-supported recyclable NC palladacycle catalyst for Heck cross-coupling reactions
    Authors: K. Karami, Z.K. Moghadam, M. Hosseini-Kharat
    Year: 2014
    Citation: DOI: 10.1016/j.catcom.2013.08.027

  • Title: Structural and theoretical studies of mono and di-insertion of symmetric alkynes into the Pd-C σ bond of cyclopalladated secondary (tert-butyl and ethyl) benzylamines
    Authors: K. Karami, M. Hosseini-Kharat, C. Rizzoli, H. Tavakol, J. Lipkowski
    Year: 2014
    Citation: DOI: 10.1016/j.jorganchem.2013.11.030

Chukwuebuka Richard Obiora | Nanomedicine | Best Researcher Award

Mr. Chukwuebuka Richard Obiora | Nanomedicine | Best Researcher Award

Senior Research Technician at CPI (Centre for Process Innovation), United Kingdom

Richard Obiora is a highly motivated and results-oriented Senior Research Technician with over 3 years of experience in drug delivery systems, including RNA-LNP therapeutics, polymeric nanoparticles, and microneedles. He has demonstrated technical expertise in nanoparticle characterization techniques such as particle sizing and zeta potential, and has contributed to drug delivery applications in vaccines and chemotherapy. His experience spans both academic and industrial settings, including his roles at CPI (Centre for Process Innovation) and Reckitt Benckiser. Richard is known for his ability to troubleshoot complex issues, collaborate effectively, and implement innovative solutions to enhance efficiency. While his early career lacks a strong record of independent publications and extensive leadership in research projects, his work in emerging fields like nanomedicine and RNA therapeutics shows significant promise. With further development in his research independence and publication record, Richard is a strong candidate for future awards and recognition.

Professional Profile 

Education🎓

Richard Obiora’s educational background includes a solid foundation in pharmaceutical and chemical sciences. He completed his undergraduate studies with a focus on biochemistry and pharmaceutical sciences, which provided him with the necessary technical knowledge to pursue advanced research in drug delivery systems. His academic journey was further strengthened through his internship at the University of Strathclyde, where he worked on synthesizing and characterizing polymeric nanoparticle-protein interactions for nanomedicine applications. This project allowed him to apply cutting-edge techniques, such as Dynamic Light Scattering (DLS) and Nanoparticle Tracking Analysis (NTA), to study the formation of protein corona and its effects on nanoparticle cellular uptake. His education has been complemented by hands-on experience in the research and development sector, which has contributed to his technical skill set and ability to collaborate on multidisciplinary research projects. This combination of academic and practical experience has shaped Richard into a well-rounded and knowledgeable researcher.

Professional Experience📝

Richard Obiora has accumulated diverse professional experience across both academic and industrial settings. Currently, as a Senior Research Technician at the Centre for Process Innovation (CPI) in the UK, he works as part of the Nanopharmaceutical team, focusing on encapsulating active pharmaceutical ingredients, such as RNA, into nanoparticles like LNPs and polymeric systems for drug delivery applications. His work includes critical tasks such as particle characterization using techniques like zeta potential and particle sizing, as well as managing downstream processing and filtration for sterilizing nanoparticle-loaded drugs. Prior to this, Richard served as a Research & Development Assistant at Reckitt Benckiser, where he contributed to developing environmentally friendly formulations for products like solar-powered Air Wick air fresheners. Additionally, he gained valuable experience during an internship at the University of Strathclyde, where he worked on characterizing nanoparticle-protein interactions for nanomedicine, further developing his skills in nanoparticle synthesis and analysis.

Research Interest🔎

Richard Obiora’s research interests lie in the development of advanced drug delivery systems, particularly focusing on nanomedicine and nanoparticle-based technologies. He is deeply involved in the encapsulation of active pharmaceutical ingredients, such as RNA, into nanoparticles like lipid nanoparticles (LNPs) and polymeric systems, with a specific emphasis on their application in vaccines and chemotherapy. His work includes studying the behavior of nanoparticles in biological systems, including their stability, particle size, and surface charge, using various analytical techniques such as Dynamic Light Scattering (DLS) and nanoparticle tracking analysis (NTA). Richard is also interested in optimizing drug delivery systems to improve therapeutic efficacy while minimizing side effects, which has significant implications for treatments in oncology and immunology. Additionally, his past research at the University of Strathclyde, focusing on polymeric nanoparticle-protein interactions, reflects his interest in understanding how nanoparticle formulations can interact with biological environments to enhance cellular uptake and improve therapeutic outcomes.

Award and Honor🏆

As of now, Richard Obiora has not been explicitly recognized with major awards or honors in his career. However, his professional trajectory reflects a strong foundation of excellence and dedication within the research field. His work at the Centre for Process Innovation (CPI), where he plays a key role in advancing nanomedicine, particularly RNA-LNP therapeutics, demonstrates his commitment to pioneering scientific developments. Richard’s ability to troubleshoot complex technical issues and lead tasks within larger projects has been instrumental in driving innovative solutions within the field of drug delivery systems. His research contributions, particularly in the synthesis, characterization, and application of nanoparticles, are highly relevant to the future of biomedical therapies, positioning him as a promising candidate for future awards and recognition. His ongoing work in nanomedicine, coupled with his cross-industry experience, suggests that Richard is well on his way to achieving significant professional milestones and recognition in the coming years.

Research Skill🔬

Richard Obiora possesses a robust set of research skills, particularly in the field of nanomedicine and drug delivery systems. He is highly skilled in nanoparticle synthesis, encapsulation techniques, and the application of various nanoparticles, such as lipid nanoparticles (LNPs) and polymeric systems, for therapeutic purposes. Richard excels in utilizing advanced characterization methods like Dynamic Light Scattering (DLS), Zetasizer, and Nanoparticle Tracking Analysis (NTA) to analyze particle size, zeta potential, and stability of drug formulations. His proficiency in techniques such as SDS-PAGE, resonance mass measurement, and Bradford/BCA assays reflects his strong analytical capabilities. Richard also has experience in downstream processing and filtration for sterilization and improving the efficiency of drug delivery systems. His research skills are complemented by a solid understanding of pharmaceutical sciences, enabling him to troubleshoot complex issues and innovate solutions to enhance the effectiveness and safety of drug delivery systems.

Conclusion💡

Richard Obiora is a very promising researcher with strong technical expertise, innovation skills, and a focused research background in highly impactful areas like RNA-LNP therapeutics and nanomedicine.
However, for a “Best Researcher Award,” which usually recognizes candidates with a substantial record of independent research, publications, and broader impact, Richard may still be in an early career stage.